SANTA MONICA, Calif., June 23, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced that the underwriters of its previously announced initial public offering have exercised in full their option to purchase an additional 1,125,000 shares of Kite Pharma's common stock at the public offering price of $17.00 per share, less customary underwriting discounts and commissions. As a result, the total number of shares being sold in the initial public offering is 8,625,000 shares. The closing of the sale of all the shares in the offering is expected to occur on June 25, 2014.
Help employers find you! Check out all the jobs and post your resume.
